Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2010 2
2011 3
2012 5
2013 16
2014 20
2015 14
2016 12
2017 11
2018 10
2019 5
2020 9
2021 13
2022 6
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos).
Fang Y, Li JX, Duangdany D, Li Y, Guo XL, Phamisith C, Yu B, Shen MY, Luo B, Wang YZ, Liu SJ, Zhao FF, Xu CC, Qiu XH, Yan R, Gui YZ, Pei RJ, Wang J, Shen H, Guan WX, Li HW, Mayxay M. Fang Y, et al. Among authors: shen h. EClinicalMedicine. 2023 Dec 13;67:102372. doi: 10.1016/j.eclinm.2023.102372. eCollection 2024 Jan. EClinicalMedicine. 2023. PMID: 38169790 Free PMC article.
Algorithm for optimized mRNA design improves stability and immunogenicity.
Zhang H, Zhang L, Lin A, Xu C, Li Z, Liu K, Liu B, Ma X, Zhao F, Jiang H, Chen C, Shen H, Li H, Mathews DH, Zhang Y, Huang L. Zhang H, et al. Among authors: shen h. Nature. 2023 Sep;621(7978):396-403. doi: 10.1038/s41586-023-06127-z. Epub 2023 May 2. Nature. 2023. PMID: 37130545 Free PMC article.
Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial.
Gui YZ, Li XN, Li JX, Shen MY, Zhang MW, Cao Y, Xu HR, Li H, Cheng J, Pan L, Yi YL, Liang LY, Yu CY, Liu GY, Yu C, Hu BJ, Zhu FC, Liang F, Shen H, Jia JY, Li HW, Zhou J, Fan J. Gui YZ, et al. Among authors: shen h. EBioMedicine. 2023 May;91:104586. doi: 10.1016/j.ebiom.2023.104586. Epub 2023 Apr 24. EBioMedicine. 2023. PMID: 37099843 Free PMC article. Clinical Trial.
An mRNA vaccine elicits STING-dependent antitumor immune responses.
Chen Z, Meng C, Mai J, Liu Y, Li H, Shen H. Chen Z, et al. Among authors: shen h. Acta Pharm Sin B. 2023 Mar;13(3):1274-1286. doi: 10.1016/j.apsb.2022.11.013. Epub 2022 Nov 17. Acta Pharm Sin B. 2023. PMID: 36970194 Free PMC article.
Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304].
Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. Rodriguez-Aguayo C, et al. Among authors: shen h. EBioMedicine. 2022 Sep;83:104194. doi: 10.1016/j.ebiom.2022.104194. Epub 2022 Jul 29. EBioMedicine. 2022. PMID: 35914489 Free PMC article. No abstract available.
119 results